PCIA
IMDX

Prime Capital Investment Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

Prime Capital Investment Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15
Closed -$1K – 489
2020
Q4 		$1K Buy
+15
New +$550 ﹤0.01% 445

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Prime Capital Investment Advisors's IMDX Position: Q1 2021 in Review

Prime Capital Investment Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q1 2021, closing a stake of 15 shares — an estimated $1K sold.

Prime Capital Investment Advisors first reported a position in IMDX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 87 funds tracked by Wall St. Rank hold IMDX as of Q1 2021.

  • Prime Capital Investment Advisors reported no remaining Insight Molecular Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 15 Insight Molecular Diagnostics shares in Q1 2021, an estimated $1K.
  • Prime Capital Investment Advisors first reported a position in Insight Molecular Diagnostics in Q4 2020 and held it in 1 quarter.
  • Prime Capital Investment Advisors's Insight Molecular Diagnostics position peaked at $1K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2021.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2021, filed 7 May 2021.